{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-056839","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.092589+00:00","generated_at":"2026-06-05T04:46:55.485667+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Shattuck Labs appoints Dr. Clay Siegall and Dr. Kate Sasser to board of directors","bullets":["Appointments effective March 1, 2024; board now includes two new independent directors.","Dr. Siegall is CEO/Chairman of Immunome (IMNM) and former CEO/Chairman of Seagen (acquired by Pfizer).","Dr. Sasser is Chief Scientific Officer of Tempus AI and previously led translational research at Genmab and J&J.","Co. expects clinical updates for SL-172154 mid-2024 and plans late-stage/pivotal studies in multiple indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-056839","json":"https://secwatch.observer/filing/0001193125-24-056839.json","markdown":"https://secwatch.observer/filing/0001193125-24-056839.md","text":"https://secwatch.observer/filing/0001193125-24-056839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000119312524056839/0001193125-24-056839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000119312524056839/d806380d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:46:55.485667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2555943aa","claim":"Dr. Clay Siegall was appointed as Class III director at Shattuck Labs, Inc..","evidence_excerpt":"On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312524056839/0001193125-24-056839-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"},{"claim_id":"db8053aabb","claim":"Dr. Kate Sasser was appointed as Class II director at Shattuck Labs, Inc..","evidence_excerpt":"On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312524056839/0001193125-24-056839-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}